Top Markets
#1 QuantixAI QuantixAI +102.23%
#2 龙虾 (Lobster) 龙虾 (Lobster) +29.81%
#3 MetaDAO MetaDAO +26.72%
#4 Pons Pons +25.79%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +25.77%
#6 Rain Rain +25.75%
#7 Bedrock Bedrock +20.69%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +19.32%
#9 Prom Prom +18.01%
#10 Ontology Gas Ontology Gas +17.84%
Coin of the day
QuantixAI QuantixAI
설정
언어
한국어
통화
USD
테마
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
주식 순위 #2542
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
주가
$11.91
시가총액
$8.11B
변동 (1일)
1.67%
변동 (1년)
-16.23%
국가
ES
거래 Grifols, S.A. (GRF)

카테고리

Healthcare
Grifols, S.A. (GRF)의 EPS
2026 기준 EPS TTM: 0
Grifols, S.A.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Grifols, S.A.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $29.85 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $8.65 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $3.55 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $20.39 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $1.26 -
US